An analysis of out-of-pocket spending on orphan drugs from 2013 to 2018 also found an increasing trend (almost doubling from 2013 to 2018) and a higher burden on payers and families despite private insurance coverage [ 80 ].
← all excerpts
Comparative policy analysis of national rare disease funding policies in Australia, Singapore, South Korea, the United Kingdom and the United States: a scoping review.
1
—
—